<?xml version="1.0"?>
<?xml-stylesheet type="text/css" href="http://www.feuxdelamour.com/v4/skins/common/feed.css?303"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="fr">
		<id>http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=4_Amazing_Things_Surrounding_Dolutegravir</id>
		<title>4 Amazing Things Surrounding Dolutegravir - Historique des versions</title>
		<link rel="self" type="application/atom+xml" href="http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=4_Amazing_Things_Surrounding_Dolutegravir"/>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=4_Amazing_Things_Surrounding_Dolutegravir&amp;action=history"/>
		<updated>2026-04-09T00:19:29Z</updated>
		<subtitle>Historique pour cette page sur le wiki</subtitle>
		<generator>MediaWiki 1.20alpha</generator>

	<entry>
		<id>http://www.feuxdelamour.com/v4/index.php?title=4_Amazing_Things_Surrounding_Dolutegravir&amp;diff=61664&amp;oldid=prev</id>
		<title>Notekey15 : Page créée avec « 384, p?[http://www.selleckchem.com/products/s-gsk1349572.html Dolutegravir clinical trial] and ��SUVmax (percentage change in SUVmax) (R2?=?0.500, p?[http://www.sellec... »</title>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=4_Amazing_Things_Surrounding_Dolutegravir&amp;diff=61664&amp;oldid=prev"/>
				<updated>2017-01-26T06:34:20Z</updated>
		
		<summary type="html">&lt;p&gt;Page créée avec « 384, p?[http://www.selleckchem.com/products/s-gsk1349572.html Dolutegravir clinical trial] and ��SUVmax (percentage change in SUVmax) (R2?=?0.500, p?[http://www.sellec... »&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Nouvelle page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;384, p?[http://www.selleckchem.com/products/s-gsk1349572.html Dolutegravir clinical trial] and ��SUVmax (percentage change in SUVmax) (R2?=?0.500, p?[http://www.selleckchem.com/products/bmn-673.html Talazoparib datasheet] of conventional and nanotherapeutic drug delivery. Copyright ? 2014 John Wiley &amp;amp; Sons, Ltd. &amp;quot;&amp;quot;High choline kinase-�� (Chk-��) expression is frequently observed in cancer cells, making it a novel target for pharmacological and molecular inhibition. As inhibiting agents are delivered systemically, it is important to determine Chk-�� expression levels in endothelial cells that line both normal and tumor vasculature, [https://en.wikipedia.org/wiki/CAPNS1 CAPNS1] and the effect of Chk-�� downregulation on these cells. Here, we characterized Chk-�� expression and the effect of its downregulation in human umbilical vein endothelial cells (HUVECs) relative to MDA-MB-231 human breast cancer cells. We used small interfering RNA (siRNA) to downregulate Chk-�� expression. Basal mRNA levels of Chk-�� were approximately three-fold lower in HUVECs relative to MDA-MB-231 breast cancer cells. Consistent with the differences in Chk-�� protein levels, phosphocholine levels were approximately 10-fold lower in HUVECs relative to MDA-MB-231 cells. Transient transfection with siRNA-Chk resulted in comparable levels of mRNA and protein in MDA-MB-231 breast cancer cells and HUVECs. However, there was a significant reduction in proliferation in MDA-MB-231 cells, but not in HUVECs.&lt;/div&gt;</summary>
		<author><name>Notekey15</name></author>	</entry>

	</feed>